Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Around the Web — 1.27.23

FDA has concluded that a new regulatory pathway for cannabidiol (CBD) products is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks and is prepared to work with Congress on this matter. “The use of CBD raises various safety concerns, especially with long-term use,” FDA said. “Studies have shown the potential for harm to the liver, interactions with certain medications, and possible harm to the male reproductive system. CBD exposure is also concerning when it comes to certain vulnerable populations such as children and those who are pregnant.” A new regulatory pathway would benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products, FDA added. Risk management tools could include clear labels, prevention of contaminants, CBD content limits, and limiting the age of purchasers to mitigate the risk of ingestion by children. In addition, a new pathway could provide access and oversight for certain CBD-containing animal products.